The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.

@article{HojjatFarsangi2014TheRT,
  title={The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.},
  author={Mohammad Hojjat-Farsangi and Ali Z. Moshfegh and Amir Hossein Daneshmanesh and Abdul Salam Khan and Eva Mikaelsson and Anders {\"O}sterborg and H{\aa}kan Mellstedt},
  journal={Seminars in cancer biology},
  year={2014},
  volume={29},
  pages={
          21-31
        }
}
Targeted cancer therapies have emerged as new treatment options for various cancer types. Among targets, receptor tyrosine kinases (RTKs) are among the most promising. ROR1 is a transmembrane RTK of importance during the normal embryogenesis for the central nervous system, heart, lung and skeletal systems, but is not expressed in normal adult tissues. However, ROR1 is overexpressed in several human malignancies and may act as a survival factor for tumor cells. Its unique expression by malignant… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

  • International journal of molecular sciences
  • 2014
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED